Philippine Health Research Registry
Display Options
Results List
Results 1 - 12 of 12 research(es) under Amang Rodriguez Memorial Medical Center

Show: All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

#
Study
         
Project Status:
Completed
Project Description:
This randomised, double-blind, multi-national, active-controlled, parallel group trial will evaluate the efficacy and safety of twice daily oral administration of empaglifozin + metformin compared with individual components of empagliflozin or metformin in drug naive patients with type 2 diabetes mellitus. The study will be conducted at about 220 s... [read more]
Project Status:
Ongoing
Project Description:
The primary hypothesis is that additional LDL-C lowering with AMG 145 when used in addition to other treatment for dyslipidemia is well tolerated and decreases the aggregate risk of cardiovascular death, myocardial infarction, hospitalization for unstable angina, stroke, and coronary revascularization in subjects with clinically evident cardiovascu... [read more]
Project Status:
Terminated
Project Description:
The drug being tested in this study is called TAK-875. TAK-875 is being tested to treat people who have diabetes. This study will look at the number of cardiovascular events (for example, hear attacks) of people who take TAK-875 in addition to standard care. The study will enroll approximately 5000 patients. Participants will be randomly assigned (... [read more]
Project Status:
Terminated
Project Description:
"The drug being tested in this study is called TAK-875. TAK-875 is being tested to treat people who have diabetes. This study will look at glycemic control in people who take TAK-875 in addition to metformin. The study will enroll approximately 620 patients. Participants will be randomly assigned (by chance, like flipping a coin) to one of the two ... [read more]
Project Status:
Ongoing
Project Description:
This trial is a multicenter, randomized, double-blind, placebo-controlled, event-driven trial that includes a main cardiovascular study and two glycemic sub-studies (see details below) and it is designed to contribute to the total number of cardiovascular endpoints from the Phase 2 and Phase 3 ertugliflozin development program. These cardiovascular... [read more]
Project Status:
Ongoing
Project Description:
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial of ertugliflozin (MK-8835/PF-04971729) in subjects with type 2 diabetes mellitus (T2DM) and Stage 3 chronic kidney disease (CKD). This trial will be conducted in conformance with Good Clinical Practices (GCP).
Project Status:
Ongoing
Project Description:
This is a multicenter, randomized, double-blind, active-comparator-controlled parallel-group clinical trial of ertugliflozin (MK-8835/PF-04971729) in subjects with type 2 diabetes mellitus (T2DM) and inadequate glycemic control on metformin monotherapy. This trial will be conducted in conformance with Good Clinical Practices (GCP).
Project Status:
Ongoing
Project Description:
The goal of this study is to assess whether canagliflozin has a renal and vascular protective effect in reducing the progression of renal impairment relative to placebo in subjects with T2DM, Stage 2 or 3 chronic kidney disease (CKD) and macroalbuminuria, who are receiving standard of care including a maximum tolerated labeled daily dose of an angi... [read more]
Project Status:
Ongoing
Project Description:
Phase 3 multi-center, randomized, parallel-group study with a 26-week,double-blind, placebo-controlled treatment period followed by a 2-week phone follow-up after the last dose of investigational product in Asian subjects with T2DM and inadequate glycemic control on metformin monotherapy
Project Status:
Ongoing
Project Description:
This is a trial of continuing sitagliptin versus withdrawing sitagliptin in participants with Type 2 diabetes mellitus (T2DM) and inadequate glycemic control who initiate and titrate insulin glargine (LANTUS®) based on a treat-to-target algorithm to achieve fasting glucose levels of 72-100 mg/dL (4-5.6 mmol/L). A primary hypothesis of this trial i... [read more]
Project Status:
Pending
Project Description:
This is an international, multicentre, event-driven, randomized, double-blind, parallel group, placebo-controlled study, evaluating the effect of dapagliflozin 10 mg versus placebo, given once daily in addition to standard of care, to prevent the progression of chronic kidney disease (CKD) or cardiovascular (CV)/renal death.
Project Status:
Ongoing
Project Description:
A multicenter, randomized, double-blind, active-controlled, parallel-group phase 3 study to evaluate the efficacy and safety of LCZ696 compared to ramipril on morbidity and mortality in high risk patients following acute myocardial infarction